Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...
pharmaphorum1d
Lilly nets Scorpion cancer drug in $2.5bn licensing deal
The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...
Reuters17d
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion
The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors. The therapy is a ...
Ibj.com16d
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors. The therapy is designed to target ...
Yahoo Finance17d
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...
The Business Journals17d
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling STX-478, its lead drug for breast cancer and other advanced solid tumors that is currently in a Phase 1/2 clinical trial. Lilly (NYSE: LLY) will pay Scorpion ...
Business Insider17d
Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily ...